Viveve Medical (NASDAQ:VIVE) announced its quarterly earnings data on Thursday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.06), Morningstar.com reports. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%. The company had revenue of $4.82 million for the quarter, compared to analyst estimates of $4.60 million.
Shares of NASDAQ:VIVE traded down $0.93 on Friday, reaching $2.32. 1,466,480 shares of the company traded hands, compared to its average volume of 355,761. Viveve Medical has a fifty-two week low of $1.60 and a fifty-two week high of $5.40. The company has a market capitalization of $103.60 million, a PE ratio of -1.10 and a beta of -0.25. The company has a debt-to-equity ratio of 3.42, a quick ratio of 4.00 and a current ratio of 4.41.
Several large investors have recently made changes to their positions in VIVE. Northern Trust Corp grew its holdings in Viveve Medical by 43.4% in the 1st quarter. Northern Trust Corp now owns 252,974 shares of the company’s stock valued at $926,000 after buying an additional 76,519 shares in the last quarter. BlackRock Inc. grew its holdings in Viveve Medical by 8.1% in the 1st quarter. BlackRock Inc. now owns 780,591 shares of the company’s stock valued at $2,857,000 after buying an additional 58,256 shares in the last quarter. LMR Partners LLP purchased a new stake in Viveve Medical in the 2nd quarter valued at $112,000. Nantahala Capital Management LLC grew its holdings in Viveve Medical by 38.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,948,132 shares of the company’s stock valued at $10,739,000 after buying an additional 1,100,928 shares in the last quarter. Finally, RTW Investments LP grew its holdings in Viveve Medical by 11.9% in the 2nd quarter. RTW Investments LP now owns 2,861,023 shares of the company’s stock valued at $7,782,000 after buying an additional 303,464 shares in the last quarter. Institutional investors own 61.98% of the company’s stock.
Separately, ValuEngine downgraded Viveve Medical from a “buy” rating to a “hold” rating in a research report on Monday, July 30th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.75.
TRADEMARK VIOLATION NOTICE: This story was published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://macondaily.com/2018/11/10/viveve-medical-vive-releases-earnings-results-misses-expectations-by-0-06-eps.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Read More: Why does a company issue an IPO?
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.